Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea
· Delayed Price · Currency is KRW 1,410.00
+59.00 (4.37%)
Mar 10, 2026, 2:35 PM KST
Xcell Therapeutics Revenue
Xcell Therapeutics had revenue of 334.59M KRW in the quarter ending September 30, 2025, a decrease of -26.92%. This brings the company's revenue in the last twelve months to 1.36B, down -29.97% year-over-year. In the year 2024, Xcell Therapeutics had annual revenue of 1.93B with 72.11% growth.
Revenue (ttm)
1.36B
Revenue Growth
-29.97%
P/S Ratio
17.15
Revenue / Employee
n/a
Employees
n/a
Market Cap
23.36B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ORIENT BIO | 59.09B |
| Oncocross | 884.68M |
| GeneOne Life Science | 30.90B |
| Amicogen | 87.97B |
| IMB Dx | 4.26B |
| CG Invites | 18.12B |
| ENCell | 5.91B |
| Macrogen | 179.98B |